questions and discussion – pharmacovigilance 2020
Published 4 years ago • 1.8K plays • Length 5:52Download video MP4
Download video MP3
Similar videos
-
54:27
fda's sentinel initiative - pharmacovigilance 2020
-
38:16
considerations for rems surveys and assessments: planning and reporting - pharmacovigilance 2020
-
34:57
icsr data quality of coding: products, adverse events and medication errors - pharmacovigilance 2020
-
41:06
division of risk management: overview of review activities and rems - pharmacovigilance 2020
-
42:22
development of shared system rems & implications of the appropriations act - pharmacovigilance 2020
-
35:16
overview of postmarketing drug safety reporting requirements - redi 2020
-
23:33
combination products: reporting device information and malfunctions - pharmacovigilance 2020
-
48:21
fda adverse event reporting system (faers) overview - pharmacovigilance 2020
-
30:07
questions and panel discussion – post-approval cmc and manufacturing - redi 2020
-
56:41
postmarket safety surveillance: tools, methods, and benefit-risk framework - pharmacovigilance 2020
-
46:22
best practices for proprietary name design – pharmacovigilance 2020
-
22:45
process for reviewing nonproprietary name suffix for biological products – pharmacovigilance 2020
-
30:38
keynote – pharmacovigilance and risk management conference 2020
-
11:14
panel questions and discussion (33of33) quality – oct. 16-17, 2019
-
45:51
panel questions and discussion (35of35) complex generics – sep. 25-26, 2019
-
37:41
rems integration initiatives - pharmacovigilance 2020
-
27:21
digital ind safety reporting - pharmacovigilance 2020
-
47:15
designing user interfaces to prevent medication errors – pharmacovigilance 2020
-
17:29
panel questions and discussion (4of8) drug registration and listing using cder direct - oct 22, 2019